JP2022518251A5 - - Google Patents
Info
- Publication number
- JP2022518251A5 JP2022518251A5 JP2021542311A JP2021542311A JP2022518251A5 JP 2022518251 A5 JP2022518251 A5 JP 2022518251A5 JP 2021542311 A JP2021542311 A JP 2021542311A JP 2021542311 A JP2021542311 A JP 2021542311A JP 2022518251 A5 JP2022518251 A5 JP 2022518251A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- hepatotoxicity
- drug
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1900811.9A GB201900811D0 (en) | 2019-01-21 | 2019-01-21 | Treatment of hepatotoxicity |
| GB1900811.9 | 2019-01-21 | ||
| GBGB1907839.3A GB201907839D0 (en) | 2019-06-03 | 2019-06-03 | Treatment of hepatotoxicity |
| GB1907839.3 | 2019-06-03 | ||
| GB1915003.6 | 2019-10-17 | ||
| GB201915003A GB201915003D0 (en) | 2019-10-17 | 2019-10-17 | Treatment of hepatotoxicity |
| PCT/EP2020/051332 WO2020152122A1 (en) | 2019-01-21 | 2020-01-21 | Treatment of hepatotoxicity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518251A JP2022518251A (ja) | 2022-03-14 |
| JP2022518251A5 true JP2022518251A5 (enExample) | 2023-01-31 |
| JP7514846B2 JP7514846B2 (ja) | 2024-07-17 |
Family
ID=69190770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542311A Active JP7514846B2 (ja) | 2019-01-21 | 2020-01-21 | 肝毒性の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11319368B2 (enExample) |
| EP (1) | EP3914621A1 (enExample) |
| JP (1) | JP7514846B2 (enExample) |
| KR (1) | KR20210138579A (enExample) |
| CN (1) | CN113677706B (enExample) |
| AU (1) | AU2020211695A1 (enExample) |
| BR (1) | BR112021014105A2 (enExample) |
| CA (1) | CA3126322A1 (enExample) |
| CL (1) | CL2021001903A1 (enExample) |
| MX (1) | MX2021008727A (enExample) |
| PH (1) | PH12021551750A1 (enExample) |
| TW (1) | TWI858005B (enExample) |
| WO (1) | WO2020152122A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4198055A4 (en) * | 2020-08-13 | 2024-08-28 | Sunshine Lake Pharma Co., Ltd. | IL-11 ANTIBODY AND ITS USE |
| WO2023006765A1 (en) * | 2021-07-26 | 2023-02-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of alcoholic liver disease |
| CN115068442A (zh) * | 2021-09-13 | 2022-09-20 | 荣灿生物医药技术(上海)有限公司 | 核酸的纳米颗粒组合物、其制备方法和用途 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| EP1566440A3 (en) | 1994-12-22 | 2005-10-19 | Genetics Institute, Inc. | Human Interleukin-11 Receptor |
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
| US5679339A (en) | 1995-06-27 | 1997-10-21 | Keith; James | Method of using IL-11 for treating spondyloarthropies |
| US6126933A (en) | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
| US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| GB9721961D0 (en) | 1997-10-16 | 1997-12-17 | Glaxo Group Ltd | Novel molecules |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| US6953777B2 (en) | 1999-03-11 | 2005-10-11 | Genetics Indtitute LLC | Use of interleukin-11 to prevent immune-mediated cytotoxicity |
| WO2000078336A1 (en) | 1999-06-21 | 2000-12-28 | Genetics Institute, Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB0021668D0 (en) | 2000-09-04 | 2000-10-18 | Smithkline Beecham Plc | New use |
| WO2004024125A1 (en) | 2002-09-16 | 2004-03-25 | Wyeth | Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same |
| JP2007537716A (ja) | 2003-12-16 | 2007-12-27 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション | サイトカイン結合ドメイン |
| EP1720562A4 (en) | 2004-01-15 | 2009-10-28 | Scios Inc | METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE |
| WO2005098041A2 (en) | 2004-03-26 | 2005-10-20 | University Of Florida Research Foundation, Inc. | Detection and treatment of fibrotic disorders |
| ATE399868T1 (de) | 2004-08-27 | 2008-07-15 | Conaris Res Inst Ag | Optimierte nukleotidsequenzen die für sgp130 kodieren |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1957097A1 (en) | 2005-12-06 | 2008-08-20 | Wyeth a Corporation of the State of Delaware | Interleukin-11 compositions and methods of use |
| JP5191393B2 (ja) | 2006-10-27 | 2013-05-08 | 国立大学法人大阪大学 | インターロイキン１１の心疾患治療薬としての利用 |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| JP5330398B2 (ja) | 2007-10-26 | 2013-10-30 | シーエスエル、リミテッド | サイトカインムテイン |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| KR101133769B1 (ko) | 2011-04-18 | 2012-04-09 | 한국생명공학연구원 | 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| CN117843785A (zh) | 2013-02-07 | 2024-04-09 | Csl有限公司 | Il-11r结合蛋白及其应用 |
| WO2014163684A1 (en) * | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| HUE072982T2 (hu) * | 2015-09-24 | 2025-12-28 | Sinew Pharma Inc | Mannitol felhasználásra hepatotoxicitás és zsírmáj betegségek kezelésében |
| CN105497893B (zh) | 2015-12-10 | 2019-02-01 | 黑龙江省科学院高技术研究院 | IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用 |
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| GB201621431D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore The | Decoy cytokine receptor |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| US20180186871A1 (en) | 2016-12-16 | 2018-07-05 | Singapore Health Services Pte Ltd. | Il-11 antibodies |
| RU2016151730A (ru) | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
| GB201806918D0 (en) | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
-
2020
- 2020-01-21 EP EP20701719.5A patent/EP3914621A1/en active Pending
- 2020-01-21 US US16/748,698 patent/US11319368B2/en active Active
- 2020-01-21 KR KR1020217026647A patent/KR20210138579A/ko active Pending
- 2020-01-21 BR BR112021014105-7A patent/BR112021014105A2/pt unknown
- 2020-01-21 JP JP2021542311A patent/JP7514846B2/ja active Active
- 2020-01-21 CA CA3126322A patent/CA3126322A1/en active Pending
- 2020-01-21 PH PH1/2021/551750A patent/PH12021551750A1/en unknown
- 2020-01-21 TW TW109102251A patent/TWI858005B/zh active
- 2020-01-21 CN CN202080010280.8A patent/CN113677706B/zh active Active
- 2020-01-21 WO PCT/EP2020/051332 patent/WO2020152122A1/en not_active Ceased
- 2020-01-21 AU AU2020211695A patent/AU2020211695A1/en active Pending
- 2020-01-21 MX MX2021008727A patent/MX2021008727A/es unknown
-
2021
- 2021-07-19 CL CL2021001903A patent/CL2021001903A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518251A5 (enExample) | ||
| Natoli et al. | Microglia-derived IL-1β promotes chemokine expression by Müller cells and RPE in focal retinal degeneration | |
| US9945870B2 (en) | Methods for determining responsiveness to an anti-CD47 agent | |
| US12269873B2 (en) | Signature of TL1A (TNFSF15) signaling pathway | |
| Marques et al. | Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation | |
| Yoon et al. | Microglial NLRP3-gasdermin D activation impairs blood-brain barrier integrity through interleukin-1β-independent neutrophil chemotaxis upon peripheral inflammation in mice | |
| Tang et al. | Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease | |
| US10822406B2 (en) | Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR) | |
| Selmi et al. | Current trends in autoimmunity and the nervous system | |
| Strecker et al. | Monocyte chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1β and G-CSF after transient focal ischemia in mice | |
| JP2022521591A5 (enExample) | ||
| JP6868655B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| US20160000936A1 (en) | Biomarkers for inflammatory disease and methods of using same | |
| Moran et al. | The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications | |
| JP2010505878A (ja) | 線維症の処置のためのｃｃｒ２アンタゴニスト | |
| Salvesen et al. | LPS-induced systemic inflammation reveals an immunomodulatory role for the prion protein at the blood-brain interface | |
| US20250334594A1 (en) | Methods for the treatment of amyotrophic lateral sclerosis | |
| Acharjee et al. | Characterization of microglial transcriptomes in the brain and spinal cord of mice in early and late experimental autoimmune encephalomyelitis using a RiboTag strategy | |
| JP2026027222A (ja) | 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節 | |
| Gaunt et al. | Cytokine enrichment in deep cerebellar nuclei is contributed by multiple glial populations and linked to reduced amyloid plaque pathology | |
| CN105764527A (zh) | 新b细胞细胞因子的鉴定 | |
| US20220162325A1 (en) | Type i interferon-mediated disorders | |
| Dohi et al. | Acute stress transiently activates macrophages and chemokines in cervical lymph nodes | |
| Ding et al. | Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage | |
| US20180057883A1 (en) | Compositions and Methods for the Diagnosis and Treatment of Lupus Nephritis |